QUB Prof Richard Wilson will present MErCuRIC at the EORTC-NCI-AARC Symposium

MErCuRIC PI, Professor Richard Wilson of Queen’s University Belfast will present “A phase I dose escalation multi-centre study crizotinib (MET inhibitor) in patients with advanced solid tumours” during a “Molecular Targeted Agents” session of the EORTC-NCI-AACR Symposium. The meeting will take place on 13-16 November 2018 in The Convention Centre Dublin.

Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2018 Symposium will assemble academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.